Myogen drops heart drug after Phase III failures

Myogen has halted development of enoximone capsules for heart failure after the treatment failed two Phase III trials. Instead, researchers will now focus on ambrisentan for the treatment of patients with pulmonary arterial hypertension and darusentan for the treatment of patients with resistant hypertension.

"We had high hopes for oral enoximone as a new therapy for the millions of patients who suffer from the debilitating symptoms of advanced chronic heart failure," said J. William Freytag, president and CEO of Denver-based Myogen. "Our experience with these patients and clinical investigators only heightens our determination to develop innovative disease modifying therapies through our drug discovery program."

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.